Background and Objectives: The aim of study is to evaluate the procedural and clinical outcomes of the PROMUS��� Everolimus-Eluting stent compared to the TAXUS Liberte��� stent in routine clinical practice. Materials and Methods: This study is a prospective, randomized, open-label, two arm, multi-center trial. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI who have coronary arteries of ��� 2.5 and ��� 3.75 mm in the reference vessel diameter with a lesion of ��� 46 mm length were randomized into everolimus-eluting stent (EES) and paclitaxel-eluting stent (PES). Primary end-points were ischemia-driven TVR at 8 months. Secondary end-points were major adverse cardiac events (MACE) such as death, myocardial infarction, ischemic driven target vessel revascularization (TVR) and stent thrombosis at 8 months. Results Total 847 patients with 1017 lesions were enrolled as 425 in EES and 422 in PES. Baseline characteristics were similar. For 8 months clinical follow-up, ischemia driven TVR was observed 2.1% in EES and 0.9% in PES group (p=0.160). Total MACE was found 3.2% in EES and 1.7% in PES group (p=0.199). Stent thrombosis was not different between two groups (0% in EES vs. 0.9% in PES, p=0.072). Conclusion The efficacy of PROMUS��� Everolimus-Eluting stent was non-inferior to TAXUS Liberte��� stent in TVR at 8 months. Further longer term follow-up data will be needed to evaluate efficacy and safety of Promus stent compared with the second generation Paclitaxel-Eluting stent. Key Words: Everolimus-Eluting stent, Paclitaxel-Eluting stent.